Table 1.
Demographic and baseline characteristics of the participants in the naltrexone and placebo groups (N=43)
| Treatment Group | Naltrexone (N=20) | Placebo (N=23) | All Patients (N=43) |
|---|---|---|---|
| Age, Mean±SD | 39.8±13.9 | 43.2±10.5 | 41.1±12.1 |
| High School Graduate, % | 95.0 | 95.7 | 95.3 |
| Female, % | 50.0 | 47.8 | 48.8 |
| White, % | 80.0 | 69.6 | 74.4 |
| Hispanic, % | 0.0 | 13.0 | 7.0 |
| Other, % | 5.0 | 4.3 | 4.7 |
| Family History of Alcoholism, % | 65.0 | 78.3 | 72.1 |
| Tobacco Use, % | 65.0 | 69.6 | 67.4 |
| Bipolar I, % | 70.0 | 73.9 | 72.1 |
| Bipolar II, % | 30.0 | 26.1 | 27.9 |
| Depressed, % | 85.0 | 82.6 | 83.7 |
| Mixed, % | 15.0 | 17.4 | 16.3 |
| Cannabis abuse, % | 25.0 | 17.4 | 20.9 |
| Cocaine abuse, % | 10.0 | 13.0 | 11.6 |
| Amphetamine abuse, % | 8.7 | 5.0 | 7.0 |
| Baseline Assessments | |||
| IDS-SR, Mean±SD | 41.3+10.9 | 45.5+10.1 | 43.5+10.5 |
| HRSD17, Mean±SD | 19.7+ 5.0 | 22.4+5.5 | 21.1+5.4 |
| YMRS, Mean±SD | 17.5+8.4 | 16.8+8.5 | 17.1+8.4 |
| PACS, Mean±SD | 22.3+5.3 | 22.5+4.1 | 22.4+4.7 |
| % of Drinking Days/Week, %±SD | 75.7+27.1 | 68.9+25.0 | 72.1+25.9 |
| % of Heavy Drinking Days/Week, %±SD | 54.3+31.6 | 54.0+27.2 | 54.2+29.0 |
| # of Drinks/Drinking Day, Mean±SD | 8.6+5.2 | 10. 0+7.4 | 9.4+6.4 |
| GGT, Mean±SD | 53.4+63.9 | 66.8+75.8 | 60.4+69.9 |
| AST, Mean±SD | 22.6+10.0 | 32.8+28.4 | 27.9+22.1 |
| ALT, Mean±SD | 23.8+19.2 | 34.6+34.9 | 29.5+28.7 |
| ASI Alcohol Score, Mean±SD | 0.5±0.3 | 0.6±0.2 | 0.6±0.3 |
| ASI Drug Score, Mean±SD | 0.0±0.0 | 0.0±0.1 | 0.0±0.1 |
| ASI Medical Score, Mean±SD | 0.3±0.3 | 0.3±0.3 | 0.3±0.3 |
| ASI Legal Score, Mean±SD | 0.0±0.0 | 0.1±0.2 | 0.0±0.1 |
| Concomitant Medications | |||
| Lithium, % | 5.0 | 13.0 | 9.3 |
| 13.0 | |||
| Total Anticonvulsants, % | 25.0 | 4.4 | 18.6 |
| Valproate, % | 20.0 | 8.7 | 11.6 |
| Lamotrigine, % | 0.0 | 0.0 | 4.7 |
| Oxcarbazepine, % | 5.0 | 2.3 | |
| Antipsychotics, % | 10.0 | 13.0 | 11.6 |
| Antidepressants, % | 40.0 | 34.8 | 37.2 |
| Sedative/Hypnotics, % | 20.0 | 13.0 | 16.3 |